ILC Therapeutics raises £3.5m to advance lead interferon drug candidate
Funds will be used for the development of hybrid interferon Alfacyte
Read More
Tag: ILC Therapeutics
Researchers assessing use of tick molecule for COVID-19
Evasins could prevent the progression of Acute Respiratory Distress Syndrome by acting as a ‘fire extinguisher’ to put out cytokine storms, researchers note
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
